Royalty Pharma agreed to purchase up to $200M in Series A Preferred Shares of Biohaven to fund Biohaven's $105M acquisition of an FDA Priority Review Voucher and general corporate uses for the rimegepant NDA. Royalty Pharma provided $125M at closing with up to an additional $75M available upon FDA acceptance of the rimegepant NDA.